(Q44229669)

1 December 2017

Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors (English)

1 reference

1 December 2017

0 references

Jerónimo Sáiz-Ruiz

1

1 reference

1 December 2017

Angela Ibáñez

2

1 reference

1 December 2017

Marina Díaz-Marsá

3

1 reference

1 December 2017

Francisco Arias

4

1 reference

1 December 2017

Jesús Padín

5

1 reference

1 December 2017

Manuel Martín-Carrasco

6

1 reference

1 December 2017

José Manuel Montes

7

1 reference

1 December 2017

Laura Ferrando

8

1 reference

1 December 2017

José Luis Carrasco

9

1 reference

1 December 2017

Eloy Martín-Ballesteros

10

1 reference

1 December 2017

Lluis Jordá

11

1 reference

1 December 2017

Lorenzo Chamorro

12

1 reference

1 December 2017

1 October 2002

1 reference

Progress in Neuro-Psychopharmacology & Biological Psychiatry

1 December 2017

1 reference

1 December 2017

26

1 reference

1 December 2017

6

1 reference

1 December 2017

1129-1134

1 reference

A comprehensive psychopathological rating scale

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900247-6

7 January 2021

Particular aspects of adverse event assessment in post marketing surveillance.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900247-6

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900247-6

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900247-6

7 January 2021

The assessment of anxiety states by rating

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900247-6

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900247-6

7 January 2021

Suicide as an outcome for mental disorders. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900247-6

7 January 2021

Efficacy of venlafaxine in depressive illness in general practice

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900247-6

7 January 2021

An evaluation of continuation therapy with tricyclic antidepressants in depressive illness

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900247-6

7 January 2021

Efficacy of Venlafaxine and Predictors of Response in a Prospective Open-Label Study of Patients With Treatment-Resistant Major Depression

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900247-6

7 January 2021

Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900247-6

7 January 2021

Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900247-6

7 January 2021

The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900247-6

7 January 2021

Sustained response to open-label venlafaxine in drug-resistant major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900247-6

7 January 2021

Cognitive therapy and pharmacotherapy for depression. Sustained improvement over one year

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900247-6

7 January 2021

Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900247-6

7 January 2021

Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900247-6

7 January 2021

Venlafaxine and treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900247-6

7 January 2021

The functioning and well-being of depressed patients. Results from the Medical Outcomes Study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900247-6

7 January 2021

10.1016/S0278-5846(02)00247-6

Identifiers

DOI

1 reference

1 December 2017

1 reference